Skip to main content
. Author manuscript; available in PMC: 2018 May 18.
Published in final edited form as: J Clin Diagn Res. 2018 Feb;12(2):DC01–DC04. doi: 10.7860/JCDR/2018/30149.11218

Table/Fig-5.

Summary of organisms used and the observed results of inhibition by compound.

Bacterium Gram Reaction Positive Control Fc-Br Fc-Cl Fc-F Fc-I Fc-Ph Fc-Py
S. aureus + Penicillin
E. coli Kanamycin
M. luteus + Penicillin +
I
+
I
P. aeruginosa Kanamycin
I, II, III
NP

I, II, III
NP
S. marcescens Kanamycin N/A
K. pneumoniae Kanamycin N/A
B. subtilis + Kanamycin +
I, II, III
+
I, II, III
+
I
+
I, II, III
N/A
P. vulgaris Kanamycin N/A
E. aerogenes Kanamycin N/A

4-fluorophenyl ferrocenecarboxylate (Fc-4F-Ph), 4-chlorophenyl ferrocenecarboxylate (Fc-4-Cl-Ph), 4-bromophenyl ferrocenecarboxylate (Fc-4Br-Ph), 4-iodophenyl ferrocenecarboxylate (Fc-4I-Ph), and their analog replacing the halide with a redox active specie 4-(1H-pyrrol-1-yl)-phenylferrocenecarboxylate (Fc-Py). Bacteria, gram-staining, antibiotic controls and concentrations (I: concentration I; II: concentration II; III: concentration III) used of ferrocenecarboxylates, with corresponding outcome.

(−): No inhibition observed; (+): Inhibition observed; NP: No pigmentation; N/A: not assayed